Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Operating Leases (2023 - 2025)

Camp4 Therapeutics' Operating Leases history spans 3 years, with the latest figure at $2.0 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 64.06% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, down 64.06%, while the annual FY2025 figure was $2.0 million, 64.06% down from the prior year.
  • Operating Leases for Q4 2025 was $2.0 million at Camp4 Therapeutics, down from $6.3 million in the prior quarter.
  • Across five years, Operating Leases topped out at $8.5 million in Q4 2023 and bottomed at $2.0 million in Q4 2025.
  • The 3-year median for Operating Leases is $5.5 million (2024), against an average of $5.3 million.
  • The largest YoY upside for Operating Leases was 0.03% in 2025 against a maximum downside of 64.06% in 2025.
  • A 3-year view of Operating Leases shows it stood at $8.5 million in 2023, then tumbled by 35.28% to $5.5 million in 2024, then plummeted by 64.06% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for CAMP's Operating Leases are $2.0 million (Q4 2025), $6.3 million (Q3 2025), and $3.9 million (Q2 2025).